Medizinische Universität Graz - Research portal

Go directly to the nagivation.
Go directly to the content.

Navigation/Search

Selected Publication:

SHR Neuro Cancer Cardio Lipid Metab Microb

Schlenke, P.
Protection against transfusion-associated graft-versus-host disease in blood transfusion: Is gamma-irradiation the only answer?
TRANSFUS MED HEMOTH. 2004; 31: 24-31. Doi: 10.1159/000076977
Web of Science FullText FullText_MUG

Leading authors Med Uni Graz: Schlenke Peter
Altmetrics:
Dimensions Citations:
Plum Analytics:
Scite (citation analytics):
Abstract:: Transfusion-associated graft-versus-host disease (TA-GvHD) is an infrequent, but fatal, complication associated with transfusion of any cellular blood component. At present, gamma-irradiation of cellular blood components is the only acceptable method for preventing TA-GvHD. All blood components can be subjected to gamma-irradiation, which irreversibly inactivates leukocytes, especially T lymphocytes, while preserving the functional integrity of the pharmaceutically effective cellular blood components. Pathogen inactivation technologies have been developed to eliminate the minimal transfusion-associated risks caused by viral or bacterial contaminants. The INTERCEPT(TM) Blood System for platelets is based on the use of amotosalen HCl and UVA-irradiation. It sufficiently inhibits the replication of parasitic, bacterial, and viral genomes and inactivates T cell replication and cytokine generation on at least an equivalent level to gamma-irradiation. The INTERCEPT Blood System for platelets shows great robustness in inactivating viable T lymphocytes with more than a 5 log(10) reduction in platelet concentrates, and it may have the potential to replace gamma-irradiation of platelet concentrates.
Find related publications in this database (Keywords): graft-versus-host disease; transfusion; irradiation; pathogen inactivation